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Background: Few case reports on human infections 
with the beef tapeworm Taenia saginata and the pork 
tapeworm, Taenia solium, diagnosed in Belgium have 
been published, yet the grey literature suggests a 
higher number of cases. Aim: To identify and describe 
cases of taeniasis and cysticercosis diagnosed at two 
Belgian referral medical institutions from 1990 to 
2015. Methods: In this observational study we retro-
spectively gathered data on taeniasis and cysticer-
cosis cases by screening laboratory, medical record 
databases as well a uniform hospital discharge data-
set. Results: A total of 221 confirmed taeniasis cases 
were identified. All cases for whom the causative spe-
cies could be determined (170/221, 76.9%) were found 
to be  T. saginata  infections. Of those with available 
information, 40.0% were asymptomatic (26/65), 
15.4% reported diarrhoea (10/65), 9.2% reported anal 
discomfort (6/65) and 15.7% acquired the infection 
in Belgium (11/70). Five definitive and six probable 
cases of neurocysticercosis (NCC), and two cases of 
non-central nervous system cysticercosis (non-CNS 
CC) were identified. Common symptoms and signs in 
five of the definitive and probable NCC cases were epi-
lepsy, headaches and/or other neurological disorders. 
Travel information was available for 10 of the 13 NCC 
and non-CNS CC cases; two were Belgians travelling to 
and eight were immigrants or visitors travelling from 
endemic areas. Conclusions: The current study indi-
cates that a non-negligible number of taeniasis cases 
visit Belgian medical facilities, and that cysticercosis 
is occasionally diagnosed in international travellers.
Introduction
Taenia saginata  and  Taenia solium  are the two most 
common species of tapeworms causing infection in 
humans. Cattle and pigs are intermediate hosts of  T. 
saginata  and  T. solium, respectively. They acquire 
muscular infection, cysticercosis, upon ingestion 
of  Taenia  spp. eggs shed with the stools of human 
tapeworm carriers, either through direct contact or 
indirectly via contaminated water or application of 
sewage sludge [1]. Taeniasis, an intestinal infection of 
humans with the adult tapeworm, is acquired by con-
suming undercooked infected meat and usually causes 
only mild clinical symptoms [1], with complications 
rarely occurring, e.g. intestinal obstruction [2]. In the 
case of  T. solium, humans can also acquire cysticer-
cosis upon accidental ingestion of eggs. In humans, 
the larval stage has a marked affinity for the central 
nervous system (CNS), causing a condition called 
neurocysticercosis (NCC). Epilepsy/seizures, chronic 
headaches and focal deficits are among the most com-
mon manifestations of NCC [3]. Globally, T. solium was 
ranked the first food-borne parasite of public health 
concern [4] and the leading cause of deaths from food-
borne diseases [5]. In Europe,  T. solium  was ranked 
as 10th most important food-borne parasite of public 
health concern, whereas T. saginata was ranked as the 
13th [6].
T. saginata carriers are common worldwide, including in 
Europe, yet their number is not well estimated, possibly 
because of the mild symptoms related to infection 
[7-11]. In Europe, the infection has been detected both 
in cattle and humans, suggesting ongoing transmis-
sion of the parasite [10-12]. Conversely, the presence 
of  T. solium  is considered to be restricted mainly 
to areas with poor sanitary conditions, inadequate 
hygiene, open defecation, the presence of free roaming 
pigs and poverty [13]. Human cysticercosis cases are 
found in vast areas of Africa, Asia and Latin America 
where  T. solium  is endemic [14]. However, cases have 
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also been reported in non-endemic areas, such as the 
United States (US), Canada and Europe. Recent reviews 
describe a total of 275 case reports for western Europe 
and 58 for eastern Europe for the period 1990 to 2015 
[10,11]. Cysticercosis cases diagnosed in these areas 
often arise from returning travellers and immigrants 
from endemic areas [15], as well as from untreated  T. 
solium  tapeworm carriers who would pose a risk to 
themselves, family members and other contacts in 
non-endemic areas [16-18]. It is important to obtain 
accurate epidemiological data on cysticercosis cases 
in humans and pigs, as well on taeniasis cases caused 
by  T. solium  in humans. Currently, neither taeniasis 
nor human cysticercosis are notifiable diseases in the 
European Union (EU), which limits assessment of the 
epidemiology of  T. saginata  and  T. solium  in this area 
[10,11,19].
In Belgium, few reports are available on 
human Taenia spp. infections. Only two taeniasis cases 
[20,21] and two NCC cases, diagnosed in Belgium, have 
been published and described in scholarly publications 
[22,23]. When screening grey literature, however, there 
are indications that an additional number of taenia-
sis cases have occurred in Belgium [10]. For instance, 
between 1980 and 1989, the annual sales of niclosa-
mide doses, a drug prescribed for tapeworm infection, 
i.e. taeniasis, diphyllobothriosis, hymenolepiosis, 
fluctuated between 35,000 and 60,000 [24]. In 2013, 
11,350 niclosamide doses were sold [25]. Moreover, a 
review of grey literature indicated that hospital data-
bases and national registries in Europe, including 
countries neighbouring Belgium, harbour information 
on a large number of cysticercosis cases diagnosed 
between 1990 and 2015 that have not been described 
in scholarly publications (4,901 in western Europe and 
772 in eastern Europe) [10,11].
Given the lack of information on the occurrence of tae-
niasis and human cysticercosis in Belgium, the primary 
objective of this study was to identify and describe 
cases of taeniasis and cysticercosis diagnosed in two 
Belgian referral medical institutions from 1990 to 2015. 
More specifically, we aimed to summarise the number, 
socio-demographic information, clinical features, diag-
nostic test results and treatment of taeniasis and cyst-
icercosis cases.
Methods
Study design and setting
This observational study consists of a retrospective 
analysis of data on suspected and confirmed taenia-
sis and cysticercosis cases diagnosed between 1990 
and 2015 in two Belgian referral medical institutions: 
the Institute of Tropical Medicine Antwerp (ITMA) and 
the Antwerp University Hospital (UZA). The ITMA is 
the national reference centre for tropical medicine and 
parasitic diseases in Belgium, and runs a large travel 
clinic. The UZA is a tertiary teaching hospital that hosts 
the hospitalisation unit of the ITMA. The institutions 
closely collaborate on the integrated care of patients 
with tropical diseases. Serology for cysticercosis is 
performed at the ITMA for patients of both institutions, 
while stool examination is performed at each institu-
tion separately.
Study population and data sources
The search strategy differed at the two institutes, but 
aimed for maximal data capture from available sources 
(Table 1). At the ITMA, the central laboratory database 
was searched for patients with serological and/or stool 
analyses positive for  Taenia  spp.. Following this, the 
medical files of patients positive for any of the tests 
Table 1
Characterisation of data sources for retrospective data collection of taeniasis and cysticercosis cases diagnosed at two 
referral medical institutions, Antwerp, Belgium, 1990–2015
Data source Type of data retrieved Data availability period
Institute of Tropical Medicine Antwerp (ITMA)
Central laboratory database Patients with serology and/or stool examination positive for Taenia spp. 1994–2015
Antwerp University Hospital (UZA)
Central laboratory database
Patients with submitted samples for Taenia spp.-related 
serology 
Patients with stool examination positive for Taenia spp.
1990–2015
Central medical record database Patients retrieved through keyword querya 2001–2015
Uniform hospital discharge 
dataset
Patients with registered ICD-9 code for taeniasis or 
cysticercosis (1990–2014)  
Patients with registered ICD-10 code for taeniasis or 
cysticercosis (2015)
1990–2015
ICD: International Classification of Disease.
a Tapeworm OR lintworm OR platworm OR taenias* OR tenias* OR (taenia AND (solium OR saginata)) OR (tenia AND (solium OR saginata)) OR 
neurocystic* OR cysticerc*.
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mentioned were reviewed, additional relevant data 
were collected, and an ITMA database for suspected 
taeniasis and cysticercosis cases was created. Only 
electronic files were searched, which were available 
from 1994 onwards at ITMA.
At the UZA, the first step was to search the central 
laboratory database for patients with samples sub-
mitted for  Taenia  spp.-related serology and/or stool 
examination positive for  Taenia  spp.. Additionally, 
the following keyword query was run on data for the 
period 2001 to 2015 in the central medical record data-
base: tapeworm OR lintworm OR platworm OR taenias* 
OR tenias* OR (taenia AND (solium OR saginata)) OR 
(tenia AND (solium OR saginata)) OR neurocystic* OR 
cysticerc*. Hospitals in Belgium are also required to 
register clinical data of non-ambulatory patients in the 
government-run uniform hospital discharge dataset 
(UHDDS). The UZA UHDDS was searched for patients 
with taeniasis or cysticercosis related International 
Classification of Disease (ICD)-9 (1990–2014) and 
ICD-10 diagnosis codes (2015) (see  Supplementary 
Table S1 for full list of codes and description). Medical 
records of all retrieved patients from these three 
databases at UZA were reviewed, relevant additional 
data were collected and a specific UZA database for 
suspected taeniasis and cysticercosis cases was cre-
ated after excluding duplicates within each database. 
The databases of ITMA and UZA were then merged and 
checked for duplicates, which were excluded from fur-
ther analysis.
Figure 1
Case retrieval strategy for taeniasis and cysticercosis cases diagnosed at two referral medical institutions, Antwerp, Belgium, 
1990–2015
Central medical 
record databasea
150 patients
78 patients
49 patients with insuﬃcient data
20 patients with negative stool result
Following further review:
Following further reviewf:
Screening for relevancee:
226 patients
126 patients
290 patients
5 definitive NCC cases
6 probable NCC cases
2 definitive non-CNS CC cases
221 taeniosis cases
28 possible NCC cases
51 unlikely NCC cases
19 patients with other diagnosis
 4 patients with insuﬃcient data
115 patients 
shortlisted
341 patients
212 patients 223 patients
Duplicates:
8 patients
Duplicates:
5 patients (TS)
36 patients (CC)
Patients not found in central medical 
record database: 3 patients
68 patients 30 patients 435 patients
Central laboratory 
databaseb
Uniform hospital 
discharge datasetc
Central laboratory 
databased
UZA
UZA TS UZA CC
UZA-ITMA TS UZA-ITMA CC
ITMA TS ITMA CC
ITM
CC: cysticercosis; NCC: neurocysticercosis; ITMA: Institute of Tropical Medicine Antwerp: TS: taeniasis; UZA: Antwerp University Hospital.
a Search for patients retrieved through keyword search.
b Search for patients with samples submitted for Taenia spp. related serology and/or stool examination positive for Taenia spp..
c Search for patients with registered International Classification of Disease (ICD)-9 code (1990–2014) and/or ICD-10 code (2015) for taeniasis 
or cysticercosis.
d Search for patients with positive serological test results and/or positive stool analysis results.
e Shortlisting based on screening for relevance (i.e. cysticercosis-related signs or symptoms, being registered with an ICD code for 
cysticercosis or any mentioning of cysticercosis as part of a differential diagnosis).
f Detailed additional review of medical files by two medical doctors with expertise in tropical medicine.
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Case definition
A taeniasis case was considered confirmed 
when  Taenia  spp. eggs or proglottids were identified 
upon stool examination, or where an ITMA/UZA physi-
cian witnessed an adult Taenia spp., e.g. during surgery. 
As eggs of Taenia spp. cannot be distinguished in stool, 
species identification, i.e. the differentiation of T. sagi-
nata vs T. solium, was based on the number of uterine 
branches in expelled proglottids when available.
Patients in the cysticercosis database were first listed 
based on the presence of cysticercosis-related signs or 
symptoms, being registered with an ICD code for cyst-
icercosis or any mentioning of cysticercosis as part of 
a differential diagnosis. Subsequently, patients on the 
list were evaluated by two medical doctors experienced 
in tropical medicine, and ultimately classified as fol-
lowing: definitive NCC case, probable NCC case (both 
based on the revised Del Brutto criteria [26]), defini-
tive non-CNS CC case (based on anatomopathology 
results), unlikely NCC or non-CNS CC case (i.e. medical 
files indicate atypical symptoms and imaging results), 
patient with other definitive diagnosis (i.e. medical file 
mentions final diagnosis different from NCC or non-
CNS CC diagnosis), or patient with insufficient informa-
tion available to allow full evaluation.
Variables
Variables collected for the taeniasis database were: 
demographic information, country of origin, travel his-
tory (with no restriction in time), stool examination 
results, clinical presentation, treatment and outcome. 
Variables collected for the cysticercosis database 
were: demographic information, travel and immigra-
tion history, clinical presentation, results of stool 
microscopy and antibody- or antigen-based serologi-
cal tests for Taenia spp. as well as for other helminths 
whenever available (i.e.  Echinococcus  spp.,  Fasciola 
spp., filariae,  Schistosoma  spp.,  Strongyloides sterc-
oralis, Toxocara spp. and Trichinella spp.), imaging and 
treatment.
Diagnostic tools
At both institutions, stool parasitological analyses are 
run for  Taenia  spp. detection, i.e. direct microscopic 
examination and parasitological examination after 
enrichment.
ITMA conducts the serological analyses for T. solium for 
both institutions. It runs a qualitative  T. solium  IgG 
antibody (Ab) test using the commercial Cysticercosis 
Serum Microwell ELISA kit (DRG International Inc., 
Springfield, New Jersey, US). The manufacturer reports 
a sensitivity (Se) of 87% (95%CI: 69.3–96.2%) and 
a specificity (Sp) of 96% (95%CI: 85.7–99.5%), and 
mentions the possibility of cross-reactions in case 
of Echinococcus spp. infections. Results are expressed 
as negative or positive. Furthermore, the ITMA performs 
a  T. solium  antigen (Ag) test using the commercial 
Cysticercosis Ag ELISA kit (apDia, Turnhout, Belgium), 
with a reported overall (both viable and dead cysts) Se 
of 94.0% (95%CI: 87.4–97.8%). In a panel of Peruvian 
samples from a non-endemic area, the Sp was 100.0% 
(95%CI: 83.2–100.0%), whereas in a group of Belgian 
blood donors, the Sp was 99.3% (97.6–99.9%), accord-
ing to the manufacturer. Results are expressed as 
Figure 2
Confirmed taeniasis cases by sex diagnosed at two referral medical institutions, Antwerp, Belgium, 1990–2015 (n = 216a)
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a Of 221 confirmed taeniasis cases, there were five missing values.
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negative (optimal density (OD) ≤ 0.8), positive (OD ≥ 1.3) 
or inconclusive (0.8 < OD < 1.3).
Data retrieval
A total of 683 patients were retrieved from the UZA 
and ITMA databases (Figure 1). After duplicate removal 
within each institute, taeniasis and cysticercosis data-
bases were created for each institution, and then 
merged per condition. The merged ITMA-UZA taeniasis 
database contained data for 290 patients, whereas the 
merged ITMA-UZA cysticercosis database contained 
data for 341 patients. Merged databases then under-
went a final check for duplicates and critical review of 
medical files.
Merged taeniasis database
In the merged ITMA-UZA taeniasis database (290 
patients), 69 patients were excluded on the basis of a 
negative stool test result (n = 20) or there being insuf-
ficient data to evaluate the case further (n = 49). The 
final dataset contained 221 confirmed taeniasis cases.
Of the eight patients with a taeniasis-related ICD-9 or 
ICD-10 code registered, only two cases could be con-
firmed: one had a positive stool test result while an 
adult  Taenia  spp. was seen and removed during an 
unrelated laparoscopic procedure for the other. Both 
cases were added to the dataset. Of the remaining six, 
one had a negative stool sample analysed and five 
lacked information on why they were registered as tae-
niasis cases.
Merged cysticercosis database
The merged ITMA-UZA cysticercosis database con-
tained 341 potential cysticercosis patients (Figure 
1). Medical records of these patients were screened 
for relevance (i.e. cysticercosis-related symptoms or 
signs, mentioning of cysticercosis in medical record, or 
registered ICD code for cysticercosis), with a shortlist 
of 115 patients resulting. Of these, 102 were excluded 
after additional detailed review of medical records by 
two medical doctors with experience in tropical medi-
cine: 28 were categorised as possible NCC cases; 51 as 
unlikely NCC cases; 19 with different final diagnoses 
established; and four with insufficient information to 
render evaluation possible. The final dataset contained 
five definitive cases of NCC, six probable NCC cases 
and two definitive cases of non-CNS CC.
Of the 19 patients in the database who had a relevant 
ICD-9 or ICD-10 code registered, three were definitive 
NCC cases, three were probable NCC cases, five were 
categorised as possible NCC cases, two as unlikely 
NCC cases, two as having different diagnosis and four 
Table 2
Characteristics of definitive and probable cysticercosis cases diagnosed at two referral medical institutions, Antwerp, 
Belgium, 1990–2015
Type of cysticercosis case Age category (years)
Geographical area 
of origin Travel/immigration
Geographical area of 
travel/immigration
Definitive NCC
0–18 NA NA NA
19–30 South America Travel Western Europe
19–30 Sub-Saharan Africa Immigration Sub-Saharan Africa
19–30 Western Europe Travel South America
31–49 Western Europe Travel Central/Eastern/Southern Asia
Probable NCC
19–30 Southern Asia Immigration Southern Asia
19–30 Southern Asia Immigration Southern Asia
19–30 Sub-Saharan Africa Immigration Sub-Saharan Africa
31–49 Eastern Asia Immigration Southern Asia
31–49 Southern Asia Immigration NA
31–49 Sub-Saharan Africa Immigration NA
Definitive non-CNS CC
31–49 NA NA NA
31–49 NA NA NA
CC: cysticercosis; CNS: central nervous system; NA: not available; NCC: neurocysticercosis.
Cases were ordered by age category and then alphabetically by region of origin.
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medical files did not contain sufficient information to 
allow evaluation.
Statistical methods
Descriptive statistical analyses, i.e. the calculation 
of proportion, percentage, median and range were 
performed in R software version 3.5.1 (R Foundation, 
Vienna, Austria) [27].
Ethical statement
For this retrospective analysis, we obtained ethical 
approval from the Institutional Review Board of ITMA 
(1018/15) as well as from the UZA Ethics Committee 
(15/34/350). Both the UZA and the ITMA apply an opt-
out strategy for the use of de-identified retrospective 
medical data. After checking the final databases for 
duplicates, all names were removed and a study-spe-
cific patient code was generated. Moreover, only the 
variables of interest were extracted for the study anal-
yses and all other information was removed. Because 
of the low number of cysticercosis cases obtained 
through our search and to ensure non-identifiability of 
patients, clinical and laboratory data were presented 
separately from background variables such as demo-
graphic information, country of origin and travel his-
tory, and in a different order. Clinical and laboratory 
data were presented by year of diagnosis, whereas as 
background variables were presented by age group.
Results
Number of samples analysed
The annual number of stool samples analysed at ITMA/
UZA for parasites, including Taenia spp., for the period 
1994 to 2015 fluctuated (median: 5,108; range: 4,150–
6,786), with a sharp increase from 4,183 in 2007 to 6,595 
in 2008. This was when UZA also started running large 
numbers of stool examinations. The annual number of 
serum or cerebrospinal fluid samples analysed with 
the  T. solium  Ab ELISA gradually decreased over 1994 
to 2015, with 1,623 samples analysed in 1994 versus 
241 in 2015 (median: 492.5; range: 224–1,623). On the 
contrary, the annual number of such samples analysed 
with the  T. solium  Ag ELISA increased from 1998 (n = 
46) to 2005 (n = 507), but decreased thereafter to 163 
in 2015 (median: 237.5; range: 46–507).
Taeniasis cases
A total of 221 confirmed taeniasis cases were identi-
fied. The median number of confirmed taeniasis cases 
per year was 9, with peaks of 18 in 1998 and 24 in 
2014 (Figure 2). The median percentage of confirmed 
taeniasis cases on the total number of samples ana-
lysed for parasites (1995–2015) was 0.21% (range: 
0.06–0.35%). For 170 of 221 confirmed taeniasis cases 
(76.9%), the infection was reported to be caused by T. 
saginata, while for the other cases (23.1%), the species 
was not mentioned. No cases of taeniasis caused by T. 
solium were identified. The majority of taeniasis cases 
were male (141/216 (5 missing values (mv)); 65.3%), 
adult individuals (168/206 (15 mv); 81.6%).
Table 3
Definitive neurocysticercosis cases diagnosed at two referral medical institutions, Antwerp, Belgium, 1990–2015
Year of diagnosis 
at ITMA or UZA Clinical symptoms Serology Stool Imaging
Additional 
information
2001 None
1 month before diagnosis 
and at diagnosis: 
Ab-ELISA: neg; Ag-ELISA: 
pos 
1 month after diagnosis: 
Ag-ELISA: neg
NA
MRI: 20 lesions, with ring 
enhancement, no or slight 
oedema 
2 months after diagnosis: 
MRI: one lesion, several 
patchy zones
NA
2004 NA NA NA NA NA
2009 Epilepsy Ab-ELISA: neg Neg
MRI: 1 lesion temporo-
occipital right, perilesional 
oedema 
1 month after diagnosis: 
MRI: reduction in volume and 
perilesional oedema
No eosinophilia 
Taenia solium 
Ab/Ag-ELISA 
CSF: neg
2010
6 months before 
diagnosis: photopsia left 
eye, balance disorder, mild 
headache
Ab/Ag-ELISA: neg NA
1 month before diagnosis: 
MRI: one cystic ring-
enhancing lesion occipital 
horn right, perilesional 
oedema, one presumed 
vascular lesion frontal right
NA
2011
1 month before diagnosis: 
headache, dysesthesia, 
nausea
Ab/Ag-ELISA: neg NA
CT, MRI: one cystic lesion 
fronto-parietal left, 
perilesional oedema
No eosinophilia
Ab: antibody; Ag: antigen; CSF: cerebrospinal fluid; CT: computed tomography; ITMA: Institute of Tropical Medicine Antwerp; MRI: magnetic 
resonance imaging; neg: negative; NA: not available; pos: positive; UZA: Antwerp University Hospital.
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Ten individuals with confirmed taeniasis reported diar-
rhoea (10/65; 15.6%), six anal discomfort (6/65; 9.2%), 
five general itch (5/65; 7.7%), eight reported having 
abdominal pain (8/65; 12.3%) and 26 of 65 were asymp-
tomatic at the time of diagnosis (40.0%) (156 mv).
Treatment information was available for 30 confirmed 
taeniasis cases. Most cases were treated with praziqu-
antel (n = 19), while others were treated with niclosa-
mide (n = 5), albendazole/mebendazole (n = 2) or a 
combination of drugs (n = 4), of which three were a 
combination of niclosamide and praziquantel.
For 70 confirmed taeniasis cases there was informa-
tion on travel history. Of these, 11 (15.7%) were autoch-
thonous cases who had not travelled outside Belgium 
in the past 10 years; seven (10.0%) were considered 
allochthonous cases as they were described as recent 
immigrants or children who were recently adopted. The 
remaining 52 cases (72.3%) had travelled but it could 
not be determined whether the infection was acquired 
abroad or in Belgium as the dates of travel were not 
specified.
Cysticercosis cases
Our search identified five definitive cases of NCC, 
whereas another six were categorised as probable NCC 
cases. Two definitive cases of non-CNS CC were also 
Table 4
Probable neurocysticercosis cases diagnosed at two referral medical institutions, Antwerp, Belgium, 1990–2015
Year of diagnosis 
at ITMA or UZA Clinical symptoms Serology Stool Imaging Additional information
2006
1 year before 
diagnosis and at 
diagnosis: epilepsy
NA NA MRI: several cystic lesions, frontal cyst with inflammation NA
2011
3 years before 
diagnosis: 
intermittent 
headaches, 
insomnia
10 and 8 months 
before diagnosis: 
Ab-ELISA: pos; 
Ag-ELISA: neg 7 
months before 
diagnosis: Ab-ELISA: 
neg At diagnosis: 
Ab-ELISA: pos
8 months 
before 
diagnosis: neg
MRI: cystic enhancing lesion in 
nucleus caudatus, perilesional 
oedema, superior two smaller 
cystic lesions 
5 months after diagnosis: MRI: 
reduced oedema
10 and 9 months before 
diagnosis: Schistomosa 
ELISA: pos; Strongyloides-
ELISA: pos; ELISA for 
filaria: pos 
8 months before diagnosis: 
eosinophilia 
At diagnosis: Schistosoma-
ELISA: pos; Strongyloides-
ELISA: pos
2012
Prior to the 
diagnosis: epileptic 
seizure Around 
4 months before 
diagnosis: sensory 
disorders
Ab-ELISA: neg, 
Ag-ELISA: pos NA NA NA
2012
3 years before 
diagnosis: four 
epilepsy events, 
thereafter no 
symptoms
Ab/Ag-ELISA: neg Neg
2 months before diagnosis: CT: 
intracranial lesions
At diagnosis: MRI: five 
supratentorial lesions: three 
with ring enhancement, two 
temporal right, one occipital 
right, one frontal right, one left 
parietal
Accidental finding 
ELISA for filariae: pos; 
Strongyloides-ELISA: pos
2012
8 and 6 years 
before confirmatory 
diagnosis at ITMA or 
UZAa: epilepsy 
At diagnosis: 
twitching feeling 
in foot, chronic 
headache
NA NA CT: normal; MRI: one lesion cortical frontal right NA
2012
Since 3 years before 
diagnosis: chronic 
headache 
3 months before 
diagnosis: paresis 
left leg
2 months before 
diagnosis: Ab/
Ag-ELISA: neg
NA MRI: two nodular lesions parietal cortex right
2 months before diagnosis: 
eosinophilia; Strongyloides 
PCR and ELISA: pos 
1 month before diagnosis: 
Strongyloides PCR and 
ELISA: neg 
At diagnosis: no 
eosinophilia
Ab: antibody; Ag: antigen; CT: computed tomography; ITMA: Institute of Tropical Medicine Antwerp; MRI: magnetic resonance imaging; neg: 
negative; NA: not available; pos: positive; UZA: Antwerp University Hospital.
a Diagnosis earlier established outside of ITMA or UZA.
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identified. Of the five definitive NCC cases, three were 
female and two were male, one was below 18 years old, 
three were between 19 and 30 years old and one was 
between 31 and 49 years old (Table 2). For the young-
est definitive NCC case, no information apart from 
the anatomopathological result was available. Of the 
other four definitive cases, two were born in Belgium, 
one of whom travelled to South America 1 year before 
the diagnosis and one of whom had travelled to sev-
eral countries in Asia 3 years before the diagnosis, 
one had immigrated from sub-Saharan Africa 13 years 
before the diagnosis was established and one was a 
visitor from South America. While three had a single 
lesion detected on magnetic resonance imaging (MRI), 
their symptoms and signs presented were diverse: one 
suffered from epilepsy, while the other two reported 
headaches in combination with different neurologi-
cal disorders, e.g. balance disorder and dysesthesia 
(Table 3). The remaining definitive NCC case with imag-
ing information available, in contrast, had 20 lesions, 
but exhibited no symptoms. The overall time between 
onset of symptoms and diagnosis for the definitive 
NCC cases ranged between 0 and 5 months. Of the four 
definitive NCC cases with serology available only one 
had positive  T. solium Ab-ELISA or Ag-ELISA results 
(positive Ag-ELISA).
Of the four definitive NCC cases with treatment infor-
mation available, two received anthelmintic treatment, 
one underwent surgery and one was treated with a 
combination of anthelmintics and surgery. Anthelmintic 
treatment consisted of albendazole for three cases, 
and both praziquantel and albendazole for one case.
In the group of probable NCC cases (n = 6), one was 
female and five were male (Table 2). Two cases came 
from the Democratic Republic of the Congo, while 
the others were from India, China (Tibet), Nepal and 
Afghanistan.
One probable NCC case had a single lesion, one had 
two lesions, three had three or more lesions, and for 
one probable case, this information was not available 
(Table 4). Symptoms and signs present in the group of 
probable NCC cases included epilepsy, headache and 
other neurological disorders, e.g. partial paralysis. The 
time between onset of symptoms and diagnosis for the 
probable NCC cases ranged between 2 months and ca 
16 years.
One probable NCC case had a positive T. solium Ag-ELISA 
result only, while another had a positive Ab-ELISA 
result only. No cases had eosinophilia, except for two 
with documented concurrent helminth infection.
No information on treatment was available for one prob-
able NCC case, whereas four received an anthelmintic 
treatment with albendazole and one underwent sur-
gery. One of the probable NCC cases was an accidental 
finding during imaging for an unrelated indication.
Both cases of definitive non-CNS CC, one diagnosed 
in 2005 and one in 2008, had a single nodule in the 
abdominal skin. For the latter, the nodule was reported 
to have developed 13 years earlier. No further informa-
tion was available for these patients.
Discussion
We conducted a comprehensive retrospective inves-
tigation for taeniasis and cysticercosis cases in two 
referral medical institutions in Belgium. The total 
number of confirmed taeniasis cases retrieved for 
the study period was higher than those extracted 
from hospital/laboratory-based registries from other 
western European countries, e.g. France, Denmark, 
Portugal, but the median annual number of cases was 
lower than that reported in the epidemiological bul-
letins and national registries of the United Kingdom, 
Spain and Slovenia [10]. Confirmed taeniasis cases 
in our study reported rather mild symptoms, which 
is in line with the literature [1]. All taeniasis cases 
for whom the causative species could be identified 
were T. saginata carriers. Eleven of 70 taeniasis cases 
were acquired in Belgium. Cattle acquire bovine cyst-
icercosis through ingestion of eggs shed by human  T. 
saginata  carriers, with research in Belgium pointing 
to wastewater contaminating pastures as a source of 
infection [28]. A recent study estimated that over 33% 
of Belgian cattle may be infected with T. saginata [29], 
suggesting the continued completion of the parasite’s 
lifecycle in the country. Given this and the habit of 
eating of raw or undercooked beef in Belgium, a cer-
tain risk of acquiring taeniasis remains. The continued 
transmission of  Taenia saginata  in Belgium has an 
economic impact: taeniasis has an estimated cost for 
the human health sector of up to EUR 795,858 per year, 
whereas bovine cysticercosis has an estimated cost for 
the meat industry of up to EUR 3,408,455 per year [30]. 
Furthermore, for 23.1% of taeniasis cases in our study, 
the causative species was not known and this group 
could thus potentially include some T. solium carriers. 
They would pose a risk to themselves, family members 
and other contacts with respect to cysticercosis devel-
opment [16-18]. Unfortunately, classical methods to 
examine stool cannot always distinguish species and 
molecular differentiation, although recommended, is 
not routinely done in Europe [10,11].
The number of definitive and probable cysticercosis 
cases found in our study was in line with the number 
of cases reported at the hospital/laboratory level in 
Austria, Denmark and Sweden, but much lower than the 
number of cases for Portugal, Spain the Netherlands, 
France and Italy [10]. Most cases seemed to be detected 
closer towards the end of the study period, possibly 
because of an actual increase in cases or increased 
awareness of specialists at the study institutes about 
the condition. After 2015, cysticercosis continued to 
be diagnosed at both institutes, with another three 
definitive NCC cases reported (Supplementary Table 
S2,  Supplementary Table S3). Overall, the definitive 
and probable cysticercosis cases identified in our 
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study had diverse travel, migration and age character-
istics, indicating that identifying high-risk patients for 
NCC is difficult. For some cases, it took several months 
and even years before the diagnosis was established, 
possibly because of the often non-specific signs and 
symptoms presented by patients, e.g. chronic head-
aches, and limited experience of some physicians with 
tropical diseases. Furthermore, serological test results 
are not always conclusive. For instance, commercially 
available Ab-ELISA kits are reported to exhibit low sen-
sitivity and frequent cross-reactions [31], and while 
the enzyme-linked immunoelectrotransfer blot (EITB) 
assay has a close to perfect performance in terms of 
sensitivity and specificity to detecting Ab, the test is 
expensive, cumbersome and not routinely used [32]. 
Good sensitivity and specificity were reported for the 
Ag-ELISA; but this test only detects the presence of 
viable cysticerci, the earliest stage of NCC [33]. NCC-
associated epilepsy however, is thought to occur when 
cysticerci present in the CNS start to degenerate or 
have even calcified [34,35]. Current diagnostic guide-
lines for NCC therefore advise the combined evalua-
tion of imaging results, clinical manifestations and 
exposure-related factors, e.g. serology, travel history, 
to establish the diagnosis and assess the degree of 
certainty [26].
This study has several limitations. At the ITMA, soft-
ware did not allow searching the medical records for 
certain terms or ICD codes, which means that a certain 
number of true cases may have been missed. However, 
because UZA medical records were searched for spe-
cific terms and because the ITMA and UZA databases 
were merged, the risk of missing true cases was rather 
low. In contrast, relying on positive Ab-based serology 
as one of the search criteria may have led to the inclu-
sion of false-positive cases because of cross-reactions. 
However, the thorough critical review of medical files 
allowed excluding irrelevant cases. It is noteworthy, 
that the use of ICD codes to retrieve taeniasis and cyst-
icercosis cases was not faultless as some cases with 
relevant ICD codes could not be assigned undoubt-
edly to taeniasis or cysticercosis diagnosis and there-
fore had to be excluded. Furthermore, as is inherent 
to retrospective surveys of medical files, information 
was often incomplete and a critical review of imaging 
results was not possible when they were not electroni-
cally stored. Finally, as case identification requires 
the intensive review of medical files and related ethi-
cal clearance, our study was restricted to two Belgian 
referral medical institutions. Nevertheless, we expect 
most cysticercosis cases to have received a confirma-
tory diagnosis at ITMA, as it is the national reference 
national reference centre for infectious and tropical 
diseases. As for the taeniasis cases, apart from dedi-
cated screening in adopted children and recent immi-
grants from endemic areas at ITMA and UZA, other 
large hospitals in Belgium are expected to have diag-
nosed a considerable number of cases as well during 
the study period.
Overall, the findings of the current study confirm that 
taeniasis and cysticercosis cases are consulting Belgian 
hospitals in larger numbers than reported in scholarly 
publications. As a proportion of taeniasis cases caused 
by T. saginata were acquired in Belgium, improved tae-
niasis case management, including correct treatment 
of cases and disposal of expelled tapeworms, as well 
as a multi-sectoral One Health approach are warranted 
to control the parasite’s transmission in the country. 
Furthermore, molecular differentiation of tapeworms is 
advised in order to detect T. solium carriers. Regarding 
cysticercosis, clinical awareness as well as serologi-
cal testing of individuals at risk, such as travellers and 
immigrants, with suggestive symptoms are key. Also 
the complexity of management should be highlighted 
during medical training to ensure adequate referral to, 
or supervision by experts in the field such as those in 
tropical medicine.
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